About the Program:
The ARV Therapies and Therapeutic Strategies program is a comprehensive, independent review of the 16th European AIDS Conference (EACS 2017). This program consists of five components: (1) EACS 2017 Expert Review: a 1.5 hour Internet symposium that features an overview and discussion of key presentations and posters, selected by the expert faculty discussants; (2) European Perspective on EACS 2017**: a 1.5 hour Case-based Internet symposium featuring Europe based expert faculty reviewing and discussing key presentations with a focus on clinical management and treatment in the EU; (3) Comprehensive Expert Review and Discussion of Key Presentations: an on-line, in-depth review of 8 of the key poster/presentations reviewed in the Internet symposium (4) Rapid-Fire Review of EACS 2017: a podcast that provides a brief, audio summary of the most essential data presented at the conference; and (5) From Conference to Clinic: Reviewing and Applying Data From EACS 2017: case-based live meetings during which the key data are reviewed, discussed and applied to patient care.
The EACS 2017 Expert Review will feature a panel of HIV experts reviewing and discussing key presentations on antiretroviral therapy presented at EACS 2017. The review and discussion will focus on HIV therapeutic options and developments, including: current treatment and management strategies, algorithms and recommendations, therapies in development, epidemiology, and diagnosis and clinical management of specific patient populations. This activity will enable participating health care providers caring for HIV-infected patients to become aware of and understand the data presented at this important conference and appropriately utilize those data to improve patient care. All online components of the program can be accessed at www.viraled.com.
This program is produced by the Postgraduate Institute for Medicine and ViralEd, Inc. It is not a session created by or presented at EACS 2017 and it is not sanctioned by the organizers of EACS 2017.
** The CME Internet Symposium: Expert Review on EACS 2017 component is jointly provided by the Annenberg Center for Health Sciences at Eisenhower and ViralEd, Inc. in collaboration with Postgraduate Institute for Medicine and supported by an independent educational grant from ViiV Healthcare.
This activity has been designed to meet the educational needs of physicians, physician assistants, advanced practice nurses and other health care professionals involved in the care of patients with HIV infection.
After completing this activity, the participant should be better able to:
- Use data reported at EACS 2017 for counseling, testing and antiretroviral treatment to prevent HIV infection, especially in underserved communities
- Use in a clinical setting findings from key studies on HIV/AIDS diagnosis, management, and treatment presented at EACS 2017
- Employ strategies based on studies and data presented at EACS 2017 for helping HIV-positive patients in medically underserved communities link to and stay in appropriate and effective HIV care
- Discuss with patients and colleagues the studies and data on therapies for HIV/AIDS presented at EACS 2017 and use that discussion to decide on appropriate planning of therapy for patients with HIV/AIDS
Release Date: November 6, 2017
Expiration Date: November 6, 2018
Estimated time to complete the program: 30-90 minutes
Back to Top
|José Arribas, MD
Senior Attending Physician, HIV Unit
Hospital de La Paz
Jürgen Rockstroh, MD
Professor of Medicine
Department of Medicine I
Ian Frank, MD
Professor of Medicine
Director, Clinical Therapeutics Program
Penn Center for AIDS Research
Perelman School of Medicine at the University of Pennsylvania
Renslow Sherer, MD
Professor of Medicine
Section of Infectious Diseases and Global Health
University of Chicago
Graeme Moyle, MD, MB, BS
Associate Director of HIV Research
Chelsea & Westminster Hospital
London, United Kingdom
Physician Continuing Medical Education
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Postgraduate Institute for Medicine and ViralEd, Inc. The Postgraduate Institute for Medicine is accredited by the ACCME to provide continuing medical education for physicians.
For Complete Program:
The Postgraduate Institute for Medicine designates this enduring material for a maximum of 1.50 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
For Modules: (Prevention, Naive/Experienced, Adverse Events, Hepatitis)
The Postgraduate Institute for Medicine designates this enduring material for a maximum of 0.50 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Disclosure of Conflicts of Interest
Postgraduate Institute for Medicine (PIM) requires instructors,
planners, managers and other individuals who are in a position to
control the content of this activity to disclose any real or apparent
conflict of interest (COI) they may have as related to the content of
this activity. All identified COI are thoroughly vetted and resolved
according to PIM policy. PIM is committed to providing its learners
with high quality CME activities and related materials that promote
improvements or quality in healthcare and not a specific proprietary
business interest of a commercial interest.
The faculty reported the following financial
relationships or relationships to products or devices they or their
spouse/life partner have with commercial interests related to the
content of these CME activities:
Jose Arribas, MD
- Consulting Fees: Merck, Gilead
- Fees for Non-CME/CE Services Received Directly from a Commercial Interest: ViiV, Janssen, Abbvie, BMS,Gilead, MSD
Ian Frank, MD
- Consulting Fees: Gilead
- Contracted Research: ViiV/GSK
Graeme Moyle, MD
- Fees for Non-CME/CE Services Received Directly from a Commercial Interest: BMS, Gilead, Merck, Tobira/Allergen, Teva, Mylan
Juergen Rockstroh, MD
- Consulting Fees: Abbott, Abbvie, Gilead, Janssen, Merck, ViiV
- Fees for Non-CME/CE Services Received Directly from a Commercial Interest: Abbot, Gilead, Merck
- Contracted Research: Gilead
Renslow Sherer, MD
The PIM planners and managers, Trace Hutchison,
PharmD; Samantha Mattiucci, PharmD, CHCP; Judi Smelker-Mitchek, RN, BSN and Jan Shultz, RN, MSN, CHCP
have nothing to disclose.
Instructions for Participation and Credit
There are no fees for participating and received CME credit for this activity. During the period, November 6, 2017 through November 6, 2018, participants must read the learning objectives and faculty disclosures and study the educational activity.
PIM supports Green CME by offering your Request for Credit online. If
you wish to received acknowledgment of completing this activity, please
complete the post-test and evaluation on http://www.cmeuniversity.com/. On the navigation menu, click on "Find Post-test/Evaluation by Course" and search by course ID 12247.
Upon registering and successfully completing the post-test with a score
of 70% or better and the activity evaluation, your certificate will be
made available immediately. Processing credit requests online will
reduce the amount of paper used by nearly 100,000 sheets per year.
Disclsoure of Unlabeled Use
educational activity may contain discussion of published and/or investigational
uses of agents that are not indicated by the FDA. The planners of this activity
do not recommend the use of any agent outside of the labeled indications.
opinions expressed in the educational activity are those of the faculty and do
not necessarily represent the views of the planners. Please refer to the
official prescribing information for each product for discussion of approved
indications, contraindications, and warnings.
Back to Top
Participants have an implied responsibility to use the newly acquired
information to enhance patient outcomes and their own professional
development. The information presented in this activity is not meant to
serve as a guideline for patient management. Any procedures,
medications, or other courses of diagnosis or treatment discussed or
suggested in this activity should not be used by clinicians without
evaluation of their patient's conditions and possible contraindications
on dangers in use, review of any applicable manufacturer's product
information, and comparison with recommendations of other authorities.
Supported by an independent educational grant from Gilead Sciences Medical Affairs.
This coverage is not sanctioned by the conference organizers and is not an official part of the conference proceedings.